Literature DB >> 16983747

Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases.

Suhayl Dhib-Jalbut1, Douglas L Arnold, Don W Cleveland, Mark Fisher, Robert M Friedlander, M Maral Mouradian, Serge Przedborski, Bruce D Trapp, Tony Wyss-Coray, V Wee Yong.   

Abstract

Multiple sclerosis is considered a disease of myelin destruction; Parkinson's disease (PD), one of dopaminergic neuron depletion; ALS, a disease of motor neuron death; and Alzheimer's, a disease of plaques and tangles. Although these disorders differ in important ways, they also have common pathogenic features, including inflammation, genetic mutations, inappropriate protein aggregates (e.g., Lewy bodies, amyloid plaques), and biochemical defects leading to apoptosis, such as oxidative stress and mitochondrial dysfunction. In most disorders, it remains uncertain whether inflammation and protein aggregation are neurotoxic or neuroprotective. Elucidating the mechanisms that orchestrate neuronal diseases should facilitate development of neuroprotective and neurorestorative strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16983747     DOI: 10.1016/j.jneuroim.2006.03.027

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  23 in total

1.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

2.  Late-onset Alzheimer's disease, heating up and foxed by several proteins: pathomolecular effects of the aging process.

Authors:  Felipe P Perez; David Bose; Bryan Maloney; Kwangsik Nho; Kavita Shah; Debomoy K Lahiri
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

3.  Dipyrone inhibits neuronal cell death and diminishes hypoxic/ischemic brain injury.

Authors:  Yi Zhang; Xin Wang; Sergei V Baranov; Shan Zhu; Zhihong Huang; Wendy Fellows-Mayle; Jiying Jiang; Arthur L Day; Bruce S Kristal; Robert M Friedlander
Journal:  Neurosurgery       Date:  2011-10       Impact factor: 4.654

4.  Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course.

Authors:  Mario Stampanoni Bassi; Ennio Iezzi; Doriana Landi; Fabrizia Monteleone; Luana Gilio; Ilaria Simonelli; Alessandra Musella; Georgia Mandolesi; Francesca De Vito; Roberto Furlan; Annamaria Finardi; Girolama A Marfia; Diego Centonze; Fabio Buttari
Journal:  J Neurol       Date:  2018-08-28       Impact factor: 4.849

5.  Microwave and magnetic (M(2) ) proteomics of the experimental autoimmune encephalomyelitis animal model of multiple sclerosis.

Authors:  Itay Raphael; Swetha Mahesula; Karan Kalsaria; Venkat Kotagiri; Anjali B Purkar; Manjushree Anjanappa; Darshit Shah; Vidya Pericherla; Yeshwant Lal Avinash Jadhav; Rekha Raghunathan; Michael Vaynberg; David Noriega; Nazul H Grimaldo; Carola Wenk; Jonathan A L Gelfond; Thomas G Forsthuber; William E Haskins
Journal:  Electrophoresis       Date:  2012-12       Impact factor: 3.535

Review 6.  Targeting progressive neuroaxonal injury: lessons from multiple sclerosis.

Authors:  Amit Bar-Or; Peter Rieckmann; Anthony Traboulsee; V Wee Yong
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

7.  Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.

Authors:  Ana Paula Kallaur; Edna Maria Vissoci Reiche; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Wildea Lice de Carvalho Jennings Pereira; Daniela Frizon Alfieri; Tamires Flauzino; Caio de Meleck Proença; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

8.  The nuclear factor kappaB-activator gene PLEKHG5 is mutated in a form of autosomal recessive lower motor neuron disease with childhood onset.

Authors:  Isabelle Maystadt; René Rezsöhazy; Martine Barkats; Sandra Duque; Pascal Vannuffel; Sophie Remacle; Barbara Lambert; Mustapha Najimi; Etienne Sokal; Arnold Munnich; Louis Viollet; Christine Verellen-Dumoulin
Journal:  Am J Hum Genet       Date:  2007-05-16       Impact factor: 11.025

9.  Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis.

Authors:  B Healy; P Valsasina; M Filippi; R Bakshi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-02-09       Impact factor: 10.154

10.  Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.

Authors:  Ana Paula Kallaur; Sayonara Rangel Oliveira; Andréa Name Colado Simão; Daniela Frizon Alfieri; Tamires Flauzino; Josiane Lopes; Wildea Lice de Carvalho Jennings Pereira; Caio de Meleck Proença; Sueli Donizete Borelli; Damacio Ramón Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Mol Neurobiol       Date:  2016-03-29       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.